weight loss

Novo Nordisk beats Q2 forecasts, raises 2026 outlook

Novo Nordisk, the Danish maker of weight-loss drug Wegovy, reported second-quarter adjusted operating profit that exceeded analyst expectations on Tuesday and raised its full-year 2026 outlook for the second time this year, citing stronger-than-expected sales of its GLP-1 drugs for…

Novo Nordisk partners with Vivani on semaglutide implant

Novo Nordisk has signed an agreement with Vivani Medical to evaluate NPM-139, a miniature subdermal semaglutide implant designed to deliver medication steadily over extended periods, the companies announced on Monday. The deal marks an effort by the Danish pharmaceutical giant…

GLP-1 drugs are reshaping global food spending habits

The growing use of GLP-1 weight-loss medications is driving measurable shifts in how consumers spend on food, forcing supermarkets, fast-food chains, and restaurants to rethink their offerings, according to new research published this week and in recent months across multiple…

Novo Nordisk shares climb as oral Wegovy success offsets ransomware crisis

Novo Nordisk shares climbed more than 5% on Friday as investors looked past a ransomware incident and focused on the runaway success of the company's oral Wegovy pill and approaching Medicare coverage for GLP-1 weight-loss drugs.